TCR

Lynk & Co's TCR Racing Culture Shines at the 2024 Beijing International Automotive Exhibition

Retrieved on: 
Tuesday, April 30, 2024
Auto China, Acceleration, Lynk & Co, Torque, Lynk, WTCR, History, Lynk & Co 03, TCR, CMA, Architecture, TCR World Tour, Video game

BEIJING, April 30, 2024 /PRNewswire/ -- At the 2024 Beijing International Automotive Exhibition, Lynk & Co is presently exhibiting its EM-P lineup of models, along with a plethora of "more than a car" displays and appealing European street scenes.

Key Points: 
  • BEIJING, April 30, 2024 /PRNewswire/ -- At the 2024 Beijing International Automotive Exhibition, Lynk & Co is presently exhibiting its EM-P lineup of models, along with a plethora of "more than a car" displays and appealing European street scenes.
  • The racing heritage of Lynk & Co 03 series in the TCR World Tour is the centerpiece of these attractions in the exhibition area, which attracts visitors to engage with.
  • Participants can delve into Lynk & Co's TCR racing history while experiencing interactive installations for a real track sensation.
  • As an integral part of the brand's "more than a car" concept, Lynk & Co actively promotes the trend-setting automotive sports culture.

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Retrieved on: 
Monday, April 29, 2024
Doctor of Philosophy, Flagship Pioneering, BMY, Epitope, Research, Vaccine, Repertoire, Disease, Autoimmune disease, Patient, Immunology, BMS, Immune system, Bristol Myers Squibb, TCR, Biotechnology, Pharmaceutical industry

CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Key Points: 
  • CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases.
  • The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
  • "We are excited to collaborate with Bristol Myers Squibb to combine their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases.
  • This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease."

Medigene AG reports Financial Results and Business Update for Q1 2024

Retrieved on: 
Friday, April 26, 2024
Prospectus, Synovial sarcoma, Tissue, Federal Gazette, TCE, Partnership, EUR, Stomach, European, Exercise, Frankfurt Stock Exchange, BioNTech, Regeneron Pharmaceuticals, Patient, Supervisory board, Toxicity, IIT, AACR, Senior, TCR, Annual general meeting, Annual report, Cancer, Ovarian cancer, Pharmaceutical industry

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.
  • The full Quarterly Statement Q1 2024 can be downloaded here: https://medigene.com/investors-media/reports-presentations/ .
  • The financial performance in Q1 2024 was in line with the Executive Management Board’s expectations.
  • The subscription period for the new shares commenced on April 24, 2024 and ends on May 7, 2024 at 24:00 hours (CEST).

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process

Retrieved on: 
Thursday, April 25, 2024
CTA, Synovial sarcoma, Safety, Cytokine, MD, Stomach, DP, Interferon, PD-L1, CHI, Patient, Neoplasm, CSP, DPS, CTAS, TCR, Ovarian cancer, Vaccine

Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.

Key Points: 
  • Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.
  • This process is vital for producing effective, safe, and durable TCR-T therapies," stated Kirsty Crame, MD, VP Clinical Strategy & Development.
  • Medigene has developed a streamlined 6-day manufacturing process that focuses on the enrichment of CD8+ T cells whilst simultaneously maintaining a high degree of stemness.
  • Clinical indications for MDG1015 were primarily chosen based on the high unmet medical need, expression of the target antigen and/or PD-L1.

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Clinical trial, Cancer, Abstract, Haematopoietic system, ASCO, Patient, Society, TCR, Therapy, Vaccine

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually.

Key Points: 
  • WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually.
  • Title: A Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies that Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation
    Title: Initial Data from a Phase 1, First-In-Human Clinical Trial for T-Plex, a Multiplexed, Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for Solid Tumors
    A copy of the presentation materials will be added to the “ Publications ” section of the Company’s website at tscan.com once presentations have concluded.

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Wednesday, April 24, 2024
Sale, Prospectus, Cancer, Morgan Stanley, Vanderbilt Avenue, Security (finance), Form, TD Securities, Varick Street, Patient, 2nd Floor, S-3, TCR, Attention, Therapy, Telephone, Needham & Company

Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.

Key Points: 
  • Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.
  • LifeSci Capital acted as lead manager, and BTIG, H.C. Wainwright & Co. and Needham & Company acted as co-managers for the offering.
  • The offering was made only by means of a preliminary prospectus supplement and accompanying filed with the SEC.
  • A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC.

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Retrieved on: 
Monday, April 22, 2024
Abstract, Cancer, Annual general meeting, TCR, Therapy, Gene, Cell, Society, Patient

WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.

Key Points: 
  • WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.

TScan Therapeutics Announces Closing of Upsized Public Offering

Retrieved on: 
Friday, April 19, 2024
Sale, Prospectus, Cancer, Morgan Stanley, Vanderbilt Avenue, Security (finance), Form, TD Securities, Exercise, Varick Street, Patient, 2nd Floor, TCR, Attention, Therapy, Telephone, Needham & Company

In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds to TScan from this offering were approximately $150.1 million, prior to any exercise of the underwriters’ option to purchase additional shares of voting common stock and before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan.
  • LifeSci Capital acted as lead manager, and BTIG, H.C. Wainwright & Co. and Needham & Company acted as co-managers for the offering.
  • The offering was made only by means of a preliminary prospectus supplement and accompanying filed with the SEC.

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Retrieved on: 
Wednesday, April 17, 2024
Sale, Prospectus, Cancer, Morgan Stanley, Vanderbilt Avenue, Security (finance), Form, TD Securities, Varick Street, Patient, 2nd Floor, TCR, Attention, Therapy, Telephone, Needham & Company

In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds to TScan from this offering are expected to be approximately $150.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan, assuming no exercise of the underwriters’ option to purchase additional shares of voting common stock.
  • The offering is expected to close on or about April 19, 2024, subject to customary closing conditions.
  • LifeSci Capital is acting as Lead Manager, and BTIG, H.C. Wainwright & Co. and Needham & Company are each acting as co-managers for the offering.

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Retrieved on: 
Tuesday, April 16, 2024
Sale, Prospectus, Cancer, Morgan Stanley, Vanderbilt Avenue, Security (finance), Form, TD Securities, Varick Street, Patient, 2nd Floor, S-3, TCR, Attention, Therapy, Telephone, Needham & Company

All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan.

Key Points: 
  • All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan.
  • TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering.
  • Morgan Stanley and TD Cowen are acting as joint book-running managers for the offering.
  • LifeSci Capital is acting as Lead Manager, and BTIG, H.C. Wainwright & Co. and Needham & Company are each acting as co-managers for the offering.